Zevra Therapeutics (ZVRA) News Today $8.48 +0.04 (+0.47%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024December 17 at 7:30 AM | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Position Lifted by Fmr LLCFmr LLC lifted its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 282,687.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,313,202 shares of the company's stock after purchasing an additional 2December 11, 2024 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stakeDecember 6, 2024 | uk.finance.yahoo.comZevra Therapeutics Announces Organizational ChangesDecember 6, 2024 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Buy" by BrokeragesShares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have earned an average recommendation of "Buy" from the eight analysts that are covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a stronDecember 2, 2024 | marketbeat.comVestal Point Capital LP Purchases New Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Vestal Point Capital LP acquired a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 525,000 shares of the company's stock, valued at approximately $November 29, 2024 | marketbeat.comPropel Bio Management LLC Invests $1.25 Million in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Propel Bio Management LLC bought a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 179,874 shares of the company's stock, valuNovember 26, 2024 | marketbeat.comZevra Therapeutics to Participate at Upcoming Investor ConferencesNovember 26, 2024 | globenewswire.comZevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA(TM) (arimoclomol) for Treatment of Niemann-Pick Disease Type CNovember 24, 2024 | stockhouse.comZevra Therapeutics (NASDAQ:ZVRA) Reaches New 52-Week High - Should You Buy?Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 52-Week High - Still a Buy?November 22, 2024 | marketbeat.comZevra Therapeutics Launches MIPLYFFA for Niemann-Pick DiseaseNovember 22, 2024 | msn.comResearch Analysts Offer Predictions for ZVRA FY2024 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at HC Wainwright lowered their FY2024 earnings estimates for Zevra Therapeutics in a report released on Wednesday, November 20th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings of ($1.92)November 22, 2024 | marketbeat.comZevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type CNovember 21, 2024 | globenewswire.comHC Wainwright Expects Lower Earnings for Zevra TherapeuticsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at HC Wainwright decreased their FY2028 earnings per share estimates for Zevra Therapeutics in a research report issued on Wednesday, November 20th. HC Wainwright analyst O. Livnat now expects that the company will earn $2.51 per shaNovember 21, 2024 | marketbeat.comZevra Therapeutics’ MIPLYFFA Launch Drives Strong Buy Rating Amidst Growth ProspectsNovember 20, 2024 | markets.businessinsider.comZevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday.November 20, 2024 | marketbeat.comZVRA FY2024 EPS Forecast Decreased by Cantor FitzgeraldZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Stock analysts at Cantor Fitzgerald dropped their FY2024 earnings per share (EPS) estimates for Zevra Therapeutics in a research note issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company willNovember 18, 2024 | marketbeat.comWhat is William Blair's Forecast for ZVRA FY2024 Earnings?Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at William Blair dropped their FY2024 earnings per share estimates for Zevra Therapeutics in a research note issued to investors on Wednesday, November 13th. William Blair analyst S. Corwin now anticipates that the company will postNovember 18, 2024 | marketbeat.comAnalysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter ReportNovember 16, 2024 | uk.finance.yahoo.comZevra Therapeutics: Strong Financials, Strategic FDA Approval, and Growth Prospects Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comZevra Therapeutics: Strong Financials, Strategic FDA Approval, and Growth Prospects Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comSimplify Asset Management Inc. Makes New $833,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Simplify Asset Management Inc. purchased a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 120,000 shares of theNovember 15, 2024 | marketbeat.comResearch Analysts Set Expectations for ZVRA FY2026 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, November 13th. William Blair analyst S. Corwin expects that the company will post earninNovember 15, 2024 | marketbeat.comResearch Analysts Set Expectations for ZVRA FY2024 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at Roth Capital lowered their FY2024 earnings estimates for Zevra Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff now anticipates that the companyNovember 15, 2024 | marketbeat.comShort Interest in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Drops By 21.2%Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) was the target of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 3,940,000 shares, a decrease of 21.2% from the October 15th total of 5,000,000 shares. Currently, 7.5% of the company's stock are sold short. Based on an average daily volume of 851,000 shares, the days-to-cover ratio is presently 4.6 days.November 15, 2024 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Given New $23.00 Price Target at Canaccord Genuity GroupCanaccord Genuity Group lowered their target price on Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday.November 14, 2024 | marketbeat.comResearch Analysts Set Expectations for ZVRA Q4 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at Roth Capital issued their Q4 2025 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued to investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff anticipatesNovember 14, 2024 | marketbeat.comZevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comZevra Therapeutics: Strong MIPLYFFA Launch and Strategic Investments Justify Buy Rating Despite OLPRUVA ChallengesNovember 13, 2024 | markets.businessinsider.comZevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...November 13, 2024 | finance.yahoo.comJanney Montgomery Scott LLC Has $2.12 Million Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Janney Montgomery Scott LLC decreased its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 29.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 305,069 shares of the company's stNovember 13, 2024 | marketbeat.comZevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate UpdatesNovember 13, 2024 | markets.businessinsider.comWilliam Blair pharmaceuticals analysts hold analyst/industry conference callNovember 12, 2024 | markets.businessinsider.comZevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 12, 2024 | finance.yahoo.comZevra Therapeutics Q3 2024 Earnings PreviewNovember 12, 2024 | msn.comZevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual MeetingNovember 11, 2024 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of "Buy" from AnalystsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has received a consensus recommendation of "Buy" from the eight ratings firms that are presently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buyNovember 7, 2024 | marketbeat.comZevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13November 6, 2024 | globenewswire.comZevra Therapeutics (ZVRA) to Release Earnings on TuesdayZevra Therapeutics (NASDAQ:ZVRA) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643172)November 5, 2024 | marketbeat.comZevra Therapeutics (ZVRA) to Release Quarterly Earnings on TuesdayZevra Therapeutics (NASDAQ:ZVRA) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643172)November 5, 2024 | marketbeat.comZevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024October 31, 2024 | globenewswire.comSanctuary Advisors LLC Makes New $474,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Sanctuary Advisors LLC acquired a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 104,924 shares of the company's stock, valued at approximatelyOctober 17, 2024 | marketbeat.comBuy Rating Affirmed for Zevra Therapeutics Based on Strong NPV and Future Market PotentialOctober 14, 2024 | markets.businessinsider.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by BrokeragesZevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has earned an average recommendation of "Buy" from the eight brokerages that are currently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned a strong buyOctober 13, 2024 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Given Overweight Rating at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of Zevra Therapeutics in a research note on Friday.October 11, 2024 | marketbeat.comZevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...October 10, 2024 | finance.yahoo.comZevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCOctober 10, 2024 | globenewswire.comGuggenheim Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy RecommendationOctober 8, 2024 | msn.comHC Wainwright Comments on Zevra Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ZVRA)Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - HC Wainwright dropped their Q3 2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research report issued to clients and investors on Monday, September 30th. HC Wainwright analyst O. Livnat now anticipates that the cOctober 2, 2024 | marketbeat.comFY2026 Earnings Forecast for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Issued By HC WainwrightZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at HC Wainwright cut their FY2026 earnings estimates for Zevra Therapeutics in a note issued to investors on Monday, September 30th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of $0.59October 1, 2024 | marketbeat.com Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen. I urge you to watch this video now. ZVRA Media Mentions By Week ZVRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZVRA News Sentiment▼1.390.71▲Average Medical News Sentiment ZVRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZVRA Articles This Week▼23▲ZVRA Articles Average Week Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Galapagos News Xencor News Evotec News Arcutis Biotherapeutics News Arcus Biosciences News Nurix Therapeutics News Kiniksa Pharmaceuticals News Immunocore News Ocular Therapeutix News Mesoblast News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZVRA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZVRA Stock Alerts